LB Pharmaceuticals Inc (NASDAQ:LBRX) People
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Scott Garland Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Jan 7, 2026); Olema Pharmaceuticals, Inc. (Director · Since at least Oct 16, 2023); ALX Oncology Holdings Inc. (Chairman · Since at least Nov 28, 2022); Day One Biopharmaceuticals Inc (Director · Since at least Aug 16, 2021); Calithera Biosciences, Inc. (Director · Jul 10, 2020 – Jun 1, 2022 · Past); Portola Pharmaceuticals Inc (President and CEO, Director · Oct 8, 2018 – Jul 2, 2020 · Past); Karyopharm Therapeutics Inc. (Director · Nov 3, 2014 – Jun 6, 2019 · Past); Relypsa Inc (SVP & Chief Commercial Officer · Oct 31, 2014 – Sep 1, 2016 · Past); Exelixis, Inc. (EVP & Chief Commerical Officer · Oct 20, 2011 – Sep 18, 2013 · Past) | Chairman of the Board, LB Pharmaceuticals · Since at least Sep 10, 2025 |
| Heather Turner Other companies: Avalyn Pharma Inc. (Director · Since at least Apr 29, 2026); Terns Pharmaceuticals, Inc. (Director · Since at least Nov 18, 2024); Lyell Immunopharma, Inc. (Chief General Counsel · Jun 16, 2021 – Mar 16, 2022 · Past); Sangamo Therapeutics, Inc. (EVP, General Counsel & Sec. · Feb 12, 2018 – Feb 25, 2019 · Past); Atara Biotherapeutics, Inc. (Former EVP, GC & Sec. · Feb 6, 2018 – Feb 9, 2018 · Past) | Chief Executive Officer, Director · Since at least Sep 10, 2025 |
| Rekha Hemrajani Other companies: BioAge Labs, Inc. (Director · Since at least Apr 17, 2024); MaxCyte, Inc. (Non-Executive Director · Since at least Jun 29, 2022); ALX Oncology Holdings Inc. (Director · Since at least Jun 15, 2022) | Director · Since at least Sep 10, 2025 |
| Joseph Miller Other companies: Aurinia Pharmaceuticals Inc (Chief Financial Officer · Since at least Jan 1, 2021); Avalo Therapeutics, Inc. (Director · Jul 12, 2018 – Mar 31, 2022 · Past) | Chief Financial Officer · Since at least Sep 2, 2026 |
| Robert Lenz Other companies: NovaBridge Biosciences (Director · Since at least Mar 18, 2026); Neumora Therapeutics, Inc. (Head of R&D · Sep 14, 2023 – Feb 18, 2025 · Past) | Director · Since at least Mar 6, 2026 |
| Ellen Rose Other companies: Lyell Immunopharma, Inc. (Senior Vice President, Communications and Investor Relations · Since at least Dec 7, 2025) | Senior Vice President, Corporate Affairs · Since at least Oct 15, 2026 |
| Ran Nussbaum Other companies: Keros Therapeutics, Inc. (Director · Since at least May 30, 2024) | Director · Since at least Sep 10, 2025 |
| Anna Eramo | Chief Medical Officer · Since at least Sep 10, 2025 |
| Christopher Zergebel | Senior Vice President, Clinical Operations · Since at least Jun 30, 2026 |
| Gad Soffer | Chief Business Officer · Since at least Sep 10, 2025 |
| James Rawls | Senior Vice President, Regulatory Affairs · Since at least Oct 14, 2025 |
| Kaya Pai Panandiker | Chief Commercial Officer · Since at least Nov 12, 2025 |
| Marc L Panoff | Senior Vice President, Finance · Since at least Sep 10, 2025 |
| Minako Pazdera | General Counsel · Since at least Jan 21, 2026 |
| Panandiker Kaya Kamlesh Pai | Chief Commercial Officer · Since at least Nov 10, 2025 |
| Rebecca Luse | Director · Since at least Sep 10, 2025 |
| Richard A. Silva | Senior Vice President, Technical Operations · Since at least Sep 10, 2025 |
| Robert R. Ruffolo | Independent Director · Since at least Nov 5, 2026 |
| Rob Lenz | Member · Since at least May 12, 2026 |
| Susan G. Kozauer | Chief Medical Officer · Since at least Sep 14, 2026 |
| William Kane | Director · Since at least Mar 26, 2026 |
| Zachary Prensky | Director · Since at least Sep 10, 2025 |